Clinical Trial Update: Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT [Phase 1, Phase 2]

View source ↗

Summary

Novartis is conducting a Phase I/II trial of [225Ac]Ac-PSMA-R2 in PSMA-positive prostate cancer, evaluating with or without prior Lu-177 PSMA radioligand therap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• [225Ac]Ac-PSMA-R2

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING